Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Revlimid / dexamethasone (RevDex) as induction therapy prior to transplantation of peripheral blood progenitor cells for the treatment of patients with newly diagnosed multiple myeloma, Revlimid monotherapy followed by maintenance therapy. Comparison of two strategies for mobilization of peripheral blood progenitor cells [Revlimid/dexametasona (RevDex) como tratamiento de induccion previo al trasplante de celulas progenitoras de sangre periferica para el tratamiento de pacientes con mieloma multiple de nuevo diagnostico, seguido de Revlimid en monoterapia como tratamiento de mantenimiento. Comparacion de dos estrategias de movilizacion de celulas progenitoras de sangre periferica]

Trial Profile

Revlimid / dexamethasone (RevDex) as induction therapy prior to transplantation of peripheral blood progenitor cells for the treatment of patients with newly diagnosed multiple myeloma, Revlimid monotherapy followed by maintenance therapy. Comparison of two strategies for mobilization of peripheral blood progenitor cells [Revlimid/dexametasona (RevDex) como tratamiento de induccion previo al trasplante de celulas progenitoras de sangre periferica para el tratamiento de pacientes con mieloma multiple de nuevo diagnostico, seguido de Revlimid en monoterapia como tratamiento de mantenimiento. Comparacion de dos estrategias de movilizacion de celulas progenitoras de sangre periferica]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 25 Aug 2011 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top